The issuer is solely responsible for the content of this announcement.

However, one industry observer cautions against moving forward with specific GLP-1 claims on packaging until federal agencies ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Share on Pinterest GLP-1 drugs may protect the brain from inflammation, some studies say, but others warn they may increase depression risk. Image credit: James Manning – PA Images/Getty Images.

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

This indicates that GLP-1 receptor agonists lead to greater reduction in overall body fat than that in muscle mass, resulting in an overall body fat percentage decrease of around 4.5%.

ORLANDO, FLA. — What the full impact of GLP-1 medications will be on food and beverage consumption patterns is impossible to know. Use of the medications today is limited and there is much to ...

Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients ... requires a dosage form or dosage strength or ...

There’s also been concern that GLP-1 drugs might increase the risk of a rare form of thyroid cancer in patients taking immune-suppressing drugs to prevent transplant rejection, researchers added.

Lilly figures it won't have to be conservative with launch supplies of orforglipron, unlike the situation with Mounjaro and Zebpound. For its injectable GLP-1s, which were met with immense ...